Features of prediction of fatal and non-fatal cases of ischemic stroke in patients with peripheral atherosclerosis in the long-term period

Introduction. According to official statistics, stroke ranks second in the structure of mortality in Russia after coronary heart disease. Mortality and morbidity rates from this pathology among people of working age have recently increased by more than 30%. It should be clarified that the main cause influencing the development of acute cerebrovascular accident is hemodynamically significant atherosclerosis of the carotid vessels. Moreover, the pathological process itself can progress rapidly, or, on the contrary, remain stable for a long time.

Aim. To assess the features of the development of fatal and non-fatal cases of ischemic stroke and develop an optimal approach to its assessment in patients with peripheral atherosclerosis in the long-term period.

Materials and methods. The study included a group of 519 patients with atherosclerotic lesions of various vascular beds. The average age of the examined patients was 60.0 ± 8.7 years.

All persons underwent standard biochemical studies, a set of instrumental studies, in the presence of clinical manifestations that arouse suspicion of atherosclerotic lesions of the vascular pools, coronary angiography, angiography of the renal vessels, brachiocephalic arteries and arteries of the lower extremities were performed. The second stage of the work included a prospective follow-up of patients for three years with an assessment of the endpoints.

Results. In the course of the statistical analysis, it was revealed that factors such as a history of amputation of the lower limb (p = 0.048), chronic ischemia of the lower extremities (p = 0.016), atherosclerosis of the abdominal aorta (p = 0.024) influenced the risk of developing non-fatal ischemic stroke in examined patients

Conclusions. The complex analysis carried out made it possible to develop an original nomogram for assessing the risk of developing fatal and non-fatal cases of ischemic stroke in the long-term period, which can be used in real clinical practice.

1. Akpanova D.M., Berkinbayev S.F., Mussagaliyeva A.T., Ospanova D.A., Zhussupov B.S. Clinical and demographic features of patients with stroke and atrial fibrillation. Kardiologiia. 2018;58(Suppl. 9):48–57. (In Russ.) Available at: https://pubmed.ncbi.nlm.nih.gov/30312571.

2. Lindsay M.P., Norrving B., Sacco R.L., Brainin M., Hacke W., Martins S. et al. World Stroke Organization (WSO): Global Stroke Fact Sheet 2019. Int J Stroke. 2019;14(8):806–817. https://doi.org/10.1177/1747493019881353.

3. Huynh W., Kwai N., Arnold R., Krishnan A.V., Lin C.S., Vucic S., Kiernan M.C. The Effect of Diabetes on Cortical Function in Stroke: Implications for Poststroke Plasticity. Diabetes. 2017;66(6):1661–1670. https://doi.org/10.2337/db16-0961.

4. Conte S.M., Vale P.R. Peripheral Arterial Disease. Heart Lung Circ. 2018;27(4):427–432. https://doi.org/10.1016/j.hlc.2017.10.014.

5. Dahal K., Kunwar S., Rijal J., Schulman P., Lee J. Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic Kidney Disease: A Meta-Analysis of Observational Studies. Chest. 2016;149(4):951–959. https://doi.org/10.1378/chest.15-1719.

6. Cherng Y.G., Lin C.S., Shih C.C., Hsu Y.H., Yeh C.C., Hu C.J. et al. Stroke risk and outcomes in patients with chronic kidney disease or end-stage renal disease: Two nationwide studies. PLoS ONE. 2018;13(1):e0191155. https://doi.org/10.1371/journal.pone.0191155.

7. Annemans L., Packard C.J., Briggs A., Ray K.K. “Highest risk-highest benefit” strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies. Eur Heart J. 2018;39(27):2546–2550. https://doi.org/10.1093/eurheartj/ehx710.

8. Aboyans V., Ricco J.B., Bartelink M.E.L., Björck M., Brodmann M., Cohnert T. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763–816. https://doi.org/10.1093/eurheartj/ehx095.

9. Mancia G., Fagard R., Narkiewicz K., Redon J., Zanchetti A., Böhm M. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159–2199. https://doi.org/10.1093/eurheartj/eht151.

10. Mareev V.Yu., Fomin I.V., Ageev F.T., Begrambekova Yu.L., Vasyuk Yu.A., Garganeeva A.A. et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiya. 2018;(6S):8–158. (In Russ.) https://doi.org/10.18087/cardio.2475.

11. Viazzi F., Muiesan M.L., Schillaci G., Salvetti M., Pucci G., Bonino B. et al. Changes in albuminuria and cardiovascular risk under antihypertensive treatment: a systematic review and meta regression analysis. J Hypertens. 2016;34(9):1689–1697. https://doi.org/10.1097/HJH.0000000000000991.

12. Terent’ev V.P., Kobzeva N.D., Batyushin M.M., Malevannyj M.V. Renal arteries sclerotic disease features in patients with acute coronary syndrome. Nephrology (Saint-Petersburg). 2015;(5):86–90. (In Russ.) Available at: https://journal.nephrolog.ru/jour/article/view/134/135.

13. Srisilpa S., Korathanakhun P. Predictors of clinical outcome among Thai patients with atrial fibrillation-associated acute ischemic stroke. J Stroke Cerebrovasc Dis. 2020;29(7):104856. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.104856.

14. Aboyans V., Desormais I., Magne J., Morange G., Mohty D., Lacroix P. Renal Artery Stenosis in Patients with Peripheral Artery Disease: Prevalence, Risk Factors and Long-term Prognosis. Eur J Vasc Endovasc Surg. 2017;53(3):380–385. https://doi.org/10.1016/j.ejvs.2016.10.029.

15. Del Porto F., Cifani N., Proietta M., Perrotta S., Dito R., di Gioia C. et al. Regulatory T CD4 + CD25+ lymphocytes increase in symptomatic carotid artery stenosis. Ann Med. 2017;49(4):283–290. https://doi.org/10.1080/078 53890.2016.1241427.

16. Qin W., Zhang X., Yang S., Li Y., Yuan J., Yang L. et al. Risk Factors for Multiple Organ Dysfunction Syndrome in Severe Stroke Patients. PLoS ONE. 2016;11(11):e0167189. https://doi.org/10.1371/journal.pone.0167189.

17. Hanna R.M., Ferrey A., Rhee C.M., Kalantar-Zadeh K. Renal-Cerebral Pathophysiology: The Interplay Between Chronic Kidney Disease and Cerebrovascular Disease. J Stroke Cerebrovasc Dis. 2021;30(9):105461. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.105461.

18. Ankolekar S., Renton C., Sare G., Ellender S., Sprigg N., Wardlaw J.M. Relationship between poststroke cognition, baseline factors, and functional outcome: data from “efficacy of nitric oxide in stroke” trial. J Stroke Cerebrovasc Dis. 2014;23(7):1821–1829. https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.04.022.

19. Shen M.Y., Chen F.Y., Hsu J.F., Fu R.H., Chang C.M., Chang C.T. et al. Plasma L5 levels are elevated in ischemic stroke patients and enhance platelet aggregation. Blood. 2016;127(10):1336–1345. https://doi.org/10.1182/blood-2015-05-646117.

20. Kobzeva N.D., Terent’ev V.P., Zolotuhina I. Ways to optimize the prediction of vascular events in patients with acute coronary syndrome and atherosclerotic lesions of the renal arteries. IOP Conf Ser Mater Sci Eng. 2019;680(1):012046. (In Russ.) Available at: https://iopscience.iop.org/article/10.1088/1757-899X/680/1/012011.

21. Qureshi A.I., Huang W., Lobanova I., Barsan W.G., Hanley D.F., Hsu C.Y. et al. Outcomes of Intensive Systolic Blood Pressure Reduction in Patients With Intracerebral Hemorrhage and Excessively High Initial Systolic Blood Pressure: Post Hoc Analysis of a Randomized Clinical Trial. JAMA Neurol. 2020;77(11):1355–1365. https://doi.org/10.1001/jamaneurol.2020.3075.

22. Kobzeva N.D., Terent’ev V.P., Batyushin M.M. Predicting the risk of post-contrast acute kidney injury in patients with acute coronary syndrome. Therapy. 2020;(4):124–130. (In Russ.) https://doi.org/10.18565/therapy.2020.4.124-130.

23. Corraini P., Henderson V.W., Ording A.G., Pedersen L., Horváth-Puhó E., Sørensen H.T. Long-Term Risk of Dementia Among Survivors of Ischemic or Hemorrhagic Stroke. Stroke. 2017;48(1):180–186. https://doi.org/10.1161/STROKEAHA.116.015242.

24. Silva G.S., Nogueira R.G. Endovascular Treatment of Acute Ischemic Stroke. Continuum (Minneap Minn). 2020;26(2):310–331. https://doi.org/10.1212/CON.0000000000000852.

25. Zhu Z., Qian S., Lu X., Xu C., Wang Y., Zhang X. et al. Protective Properties of the Extract of Chrysanthemum on Patients with Ischemic Stroke. J Healthc Eng. 2021;2021:3637456. https://doi.org/10.1155/2021/3637456.